COVID-19 Mortality Risk Factors in Kidney Transplant Recipients Identified
Coinfection increased mortality risk among kidney transplant recipients with COVID-19, a study found.
Viral Infections
Mixed Results for Paxlovid in Standard Risk Patients With COVID-19
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
Oral Antiviral Treatments for COVID-19: Molnupiravir and Paxlovid
Concise drug information for molnupiravir and Paxlovid; the FDA granted Emergency Use to both oral antiviral therapies.
Protection Against Omicron Up After Third Dose of Pfizer-BioNTech COVID-19 Vaccine
Findings demonstrated a 25-fold increase in neutralizing antibody titers in individuals who received the third dose.
FDA Approves Livtencity for Posttransplant Cytomegalovirus
Livtencity is indicated for posttransplant CMV that does not respond to available antiviral treatments
CDC Issues Alert on Omicron Variant, Provides HCP Recommendations
The CDC is recommending that health care providers take a travel history for all suspected and confirmed cases of COVID-19.
Long-Acting Antibody Combo Reduced Risk of Symptomatic COVID-19 in Phase 3 Trials
AZD7442 is a combination of 2 long-acting monoclonal antibodies, tixagevimab and cilgavimab, derived from B-cells donated by convalescent patients who were infected with the SARS-CoV-2 virus.
FDA Panel Votes on Maribavir for Post-Transplant CMV Infection
Maribavir is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates.
Posoleucel Gets Orphan Drug Status for Virus-Associated Hemorrhagic Cystitis
Posoleucel is being investigated for the treatment and prevention of serious diseases caused by 6 viral pathogens.
Long-Acting Monoclonal Antibodies Look Promising for COVID-19 Prevention
The randomized, double-blind, placebo-controlled, multicenter PROVENT trial included 5197 participants aged 18 years and older who would benefit from AZD7442.
- Loading...
Loading...
Next post in Men's Health Update
Loading... 
Loading...